Marginal zone lymphoma: present status and future perspectives

Therapeutic options for relapsed/refractory mantle cell lymphoma

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare)

Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?

New Directions for Mantle Cell Lymphoma in 2022

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Unmet supportive care needs of people with advanced cancer and their caregivers: A systematic scoping review

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

CNS prophylaxis for diffuse large B-cell lymphoma

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

1 2 3 Next